Fig. 7

Targeting PBX3 inhibits GBM invasion in vivo. a Representative images of Hematoxylin and eosin (H&E) staining of tissues from mice with orthotopic tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells. Scale bar = 500 μm. b Images of orthotopic tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells. c The tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells were weighed after imaging. **p < 0.01. d H&E staining and immunohistochemistry for PBX3, N-cadherin, ZEB1, Slug and CD44 in tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells. Scale bar = 50 μm. e Western blot analysis of PBX3, p-MEK, MEK, p-ERK1/2, ERK1/2, c-myc, LIN28, IL-6, p-STAT3, and STAT3 in tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells. f qRT-PCR analysis of let-7b expression in tumors derived from LV-siRNA-NC-U87 or LV-siRNA-PBX3-U87 cells. **p < 0.01